Canopy Growth Corp's stock surged by 23.89%, reaching a 20-day high, amid a broader market decline with the Nasdaq-100 down 1.49% and the S&P 500 down 0.78%.
This increase is attributed to reports that President Donald Trump plans to ease federal restrictions on marijuana, which has led to a significant rise in cannabis stocks, including Canopy Growth. The potential reclassification of marijuana as a Schedule III drug could attract more investment in the cannabis industry and allow banks to service cannabis companies more effectively.
The implications of this news suggest a shift in the regulatory landscape for cannabis, which could lead to increased market activity and investment opportunities in the sector, despite the overall struggles of cannabis stocks in the past year.
Wall Street analysts forecast CGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGC is 3.78 USD with a low forecast of 1.80 USD and a high forecast of 5.76 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast CGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGC is 3.78 USD with a low forecast of 1.80 USD and a high forecast of 5.76 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.190
Low
1.80
Averages
3.78
High
5.76
Current: 1.190
Low
1.80
Averages
3.78
High
5.76
Alliance Global
Neutral
maintain
$2
2025-12-15
Reason
Alliance Global
Price Target
$2
AI Analysis
2025-12-15
maintain
Neutral
Reason
Alliance Global raised the firm's price target on Canopy Growth to C$2.50 from C$2 and keeps a Neutral rating on the shares after the company announced plans to acquire MTL Cannabis in a cash and stock transaction at a total valuation of C$179M. The firm believes the combination of MTL being profitable and cash flow positive, along with providing access to quality indoor cultivation, makes the acquisition attractive, the analyst tells investors.
Benchmark
Sell -> Hold
upgrade
2025-11-10
Reason
Benchmark
Price Target
2025-11-10
upgrade
Sell -> Hold
Reason
As previously reported, Benchmark upgraded Canopy Growth to Hold from Sell following what the firm calls "another quarter of steady operational improvement." The company ended Q3 with liquidity now "sound," execution improving, and the Canadian core showing sustainable growth, prompting the firm to raise its rating, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CGC
Unlock Now
Benchmark
Mike Hickey
Sell -> Hold
upgrade
2025-11-10
Reason
Benchmark
Mike Hickey
Price Target
2025-11-10
upgrade
Sell -> Hold
Reason
Benchmark analyst Mike Hickey upgraded Canopy Growth to Hold from Sell.
Zuanic & Associates
Pablo Zuanic
Hold
Initiates
n/a
2025-03-27
Reason
Zuanic & Associates
Pablo Zuanic
Price Target
n/a
2025-03-27
Initiates
Hold
Reason
About CGC
Canopy Growth Corporation is a Canada-based cannabis company. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
